GLOBAL BLOOD THERAPEUTICS IN (GBT) Stock Analyst Ratings
USA - NASDAQ:GBT - US37890U1088 - Common Stock
68.49 USD
+0.01 (+0.01%)
68.49 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 68% to GBT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 67.97. This target is -0.77% below the current price.
GBT was analyzed by 22 analysts. The buy percentage consensus is at 68. So analysts seem to be have mildly positive about GBT.
In the last month the buy percentage fell by 15 points. So the trust of analysts is decreasing.
GBT was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-08-09 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-08-09 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-08-09 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-08-09 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-08-09 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2022-08-08 | Stifel | Downgrade | Buy -> Hold |
| 2022-08-08 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-08-08 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2022-08-08 | Jefferies | Downgrade | Buy -> Hold |
| 2022-06-28 | JP Morgan | Maintains | Neutral |
| 2022-05-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-28 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-02-24 | Oppenheimer | Maintains | Outperform |
| 2021-12-21 | SVB Leerink | Maintains | Outperform |
| 2021-12-14 | SVB Leerink | Maintains | Outperform |
| 2021-12-07 | William Blair | Upgrade | Market Perform -> Outperform |
| 2021-11-05 | RBC Capital | Maintains | Outperform |
| 2021-10-07 | Jefferies | Initiate | Buy |
| 2021-08-04 | Truist Securities | Upgrade | Hold -> Buy |
| 2021-06-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-05-06 | Roth Capital | Maintains | Buy |
| 2021-05-06 | Canaccord Genuity | Maintains | Hold |
| 2021-04-14 | SVB Leerink | Initiate | Outperform |
| 2021-03-12 | Wolfe Research | Initiate | Outperform |
GLOBAL BLOOD THERAPEUTICS IN / GBT FAQ
What is the price target for GBT stock?
22 analysts have analysed GBT and the average price target is 67.97 USD. This implies a price decrease of -0.77% is expected in the next year compared to the current price of 68.49.
Can you provide the consensus rating for GLOBAL BLOOD THERAPEUTICS IN stock?
The consensus rating for GLOBAL BLOOD THERAPEUTICS IN (GBT) is 68.1818 / 100 . This indicates that analysts generally have a neutral outlook on the stock.